Objetivo Hypertension is a common disease impacting 1 billion people worldwide, which leads to catastrophic cardiovascular complications. The cause of primary hypertension is unknown and the disease remains uncontrolled in many patients. By interrogating the key hypothesis that inflammatory dysregulation fundamentally controls development of hypertension and vascular remodelling, InflammaTENSION provides a new paradigm for the management of the disease, with the potential to lead to identification of novel therapeutic targets to control hypertension. InflammaTENSION will result in the discovery of novel biomarkers, capable of identifying patients who could benefit from such immune targeted therapies. Importantly, we already made the seminal observation that the immune system not only mediates target organ damage, but is essential for the development of hypertension. This finding has initiated numerous studies, that defined the roles of pro-inflammatory T cells, monocytes and anti-inflammatory T regulatory cells. However, our current knowledge remains very fragmented and so far has not been applied to human pathology. InflammaTENSION will for the first time advance the knowledge procured in rodent models into human studies. By combining clinical translational and model mechanistic studies it will identify novel inflammatory factors that can control immune mechanisms of hypertension. We will: (1) characterize the immunophenotypic signature of human hypertension; (2) define key concepts in cytokine biology of hypertension with TNF-α and IL-6 as key exemplars; (3) understand how chronic cytokines regulate the T cell dependent mechanisms of hypertension. InflammaTENSION will go beyond current state-of-the-art through comprehensive combination of immunology and cardiovascular medicine to create a new understanding of how the immune system may lead to human hypertension and will have major impact on the field, enabling translation of these exciting findings to clinical practice. Ámbito científico medical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepathology Palabras clave hypertension blood pressure endothelium inflammation vascular perivascular Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-2016-COG - ERC Consolidator Grant Convocatoria de propuestas ERC-2016-COG Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-COG - Consolidator Grant Institución de acogida THE UNIVERSITY OF EDINBURGH Aportación neta de la UEn € 165 243,75 Dirección OLD COLLEGE, SOUTH BRIDGE EH8 9YL Edinburgh Reino Unido Ver en el mapa Región Scotland Eastern Scotland Edinburgh Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 165 243,75 Beneficiarios (2) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo THE UNIVERSITY OF EDINBURGH Reino Unido Aportación neta de la UEn € 165 243,75 Dirección OLD COLLEGE, SOUTH BRIDGE EH8 9YL Edinburgh Ver en el mapa Región Scotland Eastern Scotland Edinburgh Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 165 243,75 UNIVERSITY OF GLASGOW Reino Unido Aportación neta de la UEn € 1 792 330,00 Dirección UNIVERSITY AVENUE G12 8QQ Glasgow Ver en el mapa Región Scotland West Central Scotland Glasgow City Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 792 330,00